Abstract：OBJECTIVE: To investigate the changes of clinical and EEG features in children with febrile seizures which are prone to epilepsy four years after antiepileptic drugs valproate and/or topiramate treatment. METHODS: One hundred and thirty-two children with febrile seizures between 2004 and 2005 and who had the indications of antiepileptic drugs treatment were administered with oral valproate and/or topiramate treatment. The children were followed up for four years. Routine blood tests, liver and renal function tests were performed twice a year. Sleeping activation EEG examination was performed once a year. RESULTS: During the follow-up of 1 to 10 years, 108 (98.2%) out of 110 children with valproate monotherapy were seizure-free. In the 110 cases, 95 were in the drug withdrawl and 10 were in the drug reduction. All of 13 cases receiving topiramate monotherapy were seizure-free and were in the drug withdrawl. None of the patients showed abnormalities in routine blood tests, liver and renal functions tests. Sleeping activation EEG showed normal in 102 cases, focal discharges in 8 cases, bilateral synchronized spikes in 4 cases and 3Hz spikes and polyspikes in 2 cases. CONCLUSIONS: Early use of antiepileptic drugs valproate or topiramate is effective and safe in children with febrile seizures which are prone to epilepsy. The majority of the children have a normal sleeping activation EEG after antiepileptic drug therapy.
QIU Peng-Ling,SHI Yi-Bin,SUN Dao-Kai et al. Clinical and EEG features in children with febrile seizures after antiepileptic drug therapy[J]. CJCP, 2011, 13(2): 123-126.
［2］Lee WL, Ong HT. Afebrile seizures associated with minor infections: comparison with febrile seizures and unprovoked seizures［J］. Pediatr Neurol, 2004, 31(3): 157-164.
［3］Scheffer IE, Berkovic SF. Generalized epilepsy with febrile seizures plus. A genetic disorder with heterogeneous clinical phenotypes［J］. Brain, 1997, 120(Pt 3): 479-490.
［4］Poduri A, Wang Y, Gordon D, Barral-Rodriguez S, Barker-Cummings C, Ulgen A, et al. Novel susceptibility locus at chromosome 6q16.3-22.31 in a family with GEFS+［J］. Neurology, 2009, 73(16): 1264-1272.
